Furthermore, a therapeutic kinase inhibitor directed against all three novel targets, FLT3, BTK, and AURK, may be able to achieve much enhanced anti-leukemia efficacy in the targeted therapy of AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.